Amgen Inc. (AMGN) Position Cut by Whittier Trust Co. of Nevada Inc.
Whittier Trust Co. of Nevada Inc. decreased its position in Amgen Inc. (NASDAQ:AMGN) by 4.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,094 shares of the medical research company’s stock after selling 500 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in Amgen were worth $1,840,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of the company. ClariVest Asset Management LLC raised its stake in Amgen by 14.3% in the second quarter. ClariVest Asset Management LLC now owns 386,472 shares of the medical research company’s stock worth $58,802,000 after buying an additional 48,271 shares during the period. Diligent Investors LLC purchased a new stake in Amgen during the second quarter worth $202,000. LMR Partners LLP raised its position in shares of Amgen by 17.2% in the second quarter. LMR Partners LLP now owns 10,952 shares of the medical research company’s stock worth $1,666,000 after buying an additional 1,606 shares during the last quarter. Flossbach Von Storch AG raised its position in shares of Amgen by 7.1% in the second quarter. Flossbach Von Storch AG now owns 1,263,342 shares of the medical research company’s stock worth $192,217,000 after buying an additional 83,610 shares during the last quarter. Finally, Sabal Trust CO raised its position in shares of Amgen by 4.4% in the second quarter. Sabal Trust CO now owns 87,754 shares of the medical research company’s stock worth $13,352,000 after buying an additional 3,663 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors and hedge funds.
Amgen Inc. (NASDAQ:AMGN) traded down 1.45% during trading on Friday, hitting $161.90. 2,817,469 shares of the stock traded hands. The stock has a market cap of $121.16 billion, a P/E ratio of 16.57 and a beta of 0.94. The stock has a 50 day moving average price of $169.59 and a 200-day moving average price of $162.28. Amgen Inc. has a 52-week low of $139.02 and a 52-week high of $176.85.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, beating analysts’ consensus estimates of $2.74 by $0.10. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.58 billion. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter last year, the firm posted $2.57 EPS. On average, analysts anticipate that Amgen Inc. will post $11.35 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 8th. Shareholders of record on Wednesday, November 16th will be issued a $1.00 dividend. This represents a $4.00 dividend on an annualized basis and a yield of 2.47%. Amgen’s payout ratio is currently 40.90%.
A number of brokerages have recently commented on AMGN. BMO Capital Markets reissued an “outperform” rating and issued a $190.00 price target on shares of Amgen in a report on Thursday, September 22nd. Jefferies Group reaffirmed a “buy” rating and set a $198.00 target price on shares of Amgen in a report on Tuesday, August 23rd. Vetr raised shares of Amgen from a “sell” rating to a “hold” rating and set a $171.34 target price on the stock in a report on Wednesday, August 3rd. Leerink Swann reaffirmed a “hold” rating on shares of Amgen in a report on Saturday, September 17th. Finally, Credit Suisse Group AG set a $206.00 target price on shares of Amgen and gave the company a “buy” rating in a report on Saturday, September 17th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $184.94.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of the firm’s stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.20% of the stock is owned by company insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.